Progress in Primary Aldosteronism: Translation on the Move

Horm Metab Res. 2015 Dec;47(13):933-4. doi: 10.1055/s-0035-1565125. Epub 2015 Dec 14.


Hypertension is a major cardiovascular risk factor that affects between 10-40% of the general population in an age dependent manner. The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure, fluid volume, and the vascular response to injury and inflammation 1. Chronic RAAS activation in the presence of sufficient sodium consumption leads to persistent hypertension, setting off a cascade of inflammatory, thrombotic, and atherogenic effects eventually leading to end-organ damage 2 3. Accordingly, numerous studies have demonstrated that elevated renin and/or aldosterone levels are predictors of adverse outcome in hypertension 4, heart failure 5 6, myocardial infarction 7, and renal insufficiency 8 and influence insulin resistance 9. Primary aldosteronism (PA) is the most common secondary form of hypertension with an estimated prevalence between 4 and 12% of hypertensives 10 11 12 and 11-20% in patients that are resistant to combined antihypertensive medication 13 14. Given the severe cardiovascular adverse effects of aldosterone excess that are independent of high blood pressure levels 15 16 17 18 detection and treatment of PA has important impact on clinical outcome and survival.

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Clinical Trials as Topic
  • Female
  • Humans
  • Hyperaldosteronism / complications
  • Hyperaldosteronism / genetics
  • Hyperaldosteronism / pathology*
  • Mutation / genetics
  • Translational Research, Biomedical*